Skip to main content

Table 3 Analysis of potential risk factors for unfavorable DTC evolution in acromegalic patients classified according to stage, initial recurrence risk, initial and follow-up response

From: Acromegaly and thyroid cancer: analysis of evolution in a series of patients

Potential risks factors for unfavorable DTC evolution

Age at diagnosis of DTC (years) Median (range)

IGF-1 at diagnosis of DTC (ULN)

Median (range)

Time between DTC diagnosis and acromegaly control (years)

Median (range)

Insulin resistance

n (%)

Stage

(n = 24)

1 (n = 19)

1.19 (0.32–4.8)

0.83 (0–7)

8 (42.1)

2 (n = 4)

 

1.52 (1.32–1.70)

2.25 (1–3.6)

1 (25)

4b (n = 1)

 

2.31

0

0

p-value

0.55

0.36

1

Initial recurrence risk

(n = 24)

Low (n = 21)

51.5 (18–68)

1.44 (0.32–4.8)

1.25 (0–7)

8 (40)

Intermediate (n = 2)

55.5 (42–69)

0.97 (0.64–1.31)

2.13 (0.66–3.6)

0

High (n = 1)

66

2.31

0

0

p-value

0.33

0.33

0.69

0.68

Initial response

(n = 23)

Excellent (n = 12)

58.5 (18–69)

1.4 (0.32–3.09)

0.5 (0–7)

6 (50)

Indeterminate (n = 7)

50 (37–68)

1.34 (0.64–4.4)

0.83 (0–2.3)

3 (42.9)

Biochemical

incomplete (n = 3)

37 (37–38)

3.37 (1.94–4.8)

3 (0.25–4)

0

Structural

Incomplete (n = 1)

66

2.31

0

0

p-value

0.40

0.65

0.79

0.42

Response at the end of follow-up

(n = 23)

No evidence of disease (n = 19)

50 (18–69)

1.21 (0.32–4.4)

1 (0–7)

7 (36.8)

Indeterminate (n = 2)

65 (62–68)

1.8 (0.98–2.6)

1.8 (0–3.6)

1 (50)

Biochemical

incomplete (n = 1)

37

1.7

0

0

Structural

Incomplete (n = 1)

66

2.31

0

0

p-value

0.23

0.30

0.87

0.71

  1. DTC differentiated thyroid cancer, IGF-1 insulin-like growth factor type 1, ULN upper limit of normality